Table 2.
Association between monocyte count and 180-day mortality in HBV-ACLF patients.
| Model | Total | G-CSF group | Control group |
|---|---|---|---|
| Monocytes on day 0 (×109/L) | |||
| Crude model | 2.42 (1.38, 4.24) 0.0020 | 5.19 (2.10, 12.82) 0.0004 | 1.72 (0.81, 3.65) 0.1599 |
| Model 1 | 2.83 (1.58, 5.07) 0.0005 | 5.41 (2.10, 13.89) 0.0005 | 2.13 (0.94, 4.83) 0.0690 |
| Model 2 | 2.86 (1.59, 5.12) 0.0004 | 5.25 (2.05, 13.46) 0.0006 | 2.32 (1.05, 5.12) 0.0365 |
| Model 3 | 2.90 (1.41, 5.93) 0.0036 | 15.48 (3.60, 66.66) 0.0002 | 2.43 (0.72, 8.20) 0.1531 |
| Monocytes on day 7 (×109/L) | |||
| Crude model | 1.79 (1.11, 2.90) 0.0180 | 1.30 (0.69, 2.45) 0.4117 | 3.09 (1.42, 6.71) 0.0044 |
| Model 1 | 1.93 (1.17, 3.19) 0.0106 | 1.27 (0.64, 2.51) 0.4972 | 3.36 (1.44, 7.85) 0.0051 |
| Model 2 | 1.96 (1.17, 3.26) 0.0102 | 1.25 (0.63, 2.47) 0.5177 | 3.73 (1.58, 8.82) 0.0027 |
| Model 3 | 1.42 (0.77, 2.61) 0.2590 | 1.10 (0.50, 2.43) 0.8080 | 2.57 (0.79, 8.44) 0.1184 |
Data are presented as HR (95% CI) and P value. Model 1 was adjusted for age and sex; Model 2 was adjusted for Model 1+ liver cirrhosis; Model 3 was adjusted for Model 2+ total bilirubin and international normalized ratio, and infection, acute kidney injury, and hepatic encephalopathy presence. G-CSF, Granulocyte-colony stimulating factor.